Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Free Cash Flow (2016 - 2025)

Organogenesis Holdings (ORGO) has 10 years of Free Cash Flow data on record, last reported at $34.8 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 358.92% year-over-year to $34.8 million; the TTM value through Dec 2025 reached -$24.5 million, down 685.73%, while the annual FY2025 figure was -$24.5 million, 685.73% down from the prior year.
  • Free Cash Flow reached $34.8 million in Q4 2025 per ORGO's latest filing, up from $844000.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $40.2 million in Q4 2021 and bottomed at -$40.0 million in Q2 2025.
  • Average Free Cash Flow over 5 years is $1.8 million, with a median of $1.3 million recorded in 2023.
  • The widest YoY moves for Free Cash Flow: up 358.92% in 2025, down 2910.48% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $40.2 million in 2021, then plummeted by 107.11% to -$2.9 million in 2022, then surged by 355.25% to $7.3 million in 2023, then rose by 3.92% to $7.6 million in 2024, then surged by 358.92% to $34.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $34.8 million in Q4 2025, $844000.0 in Q3 2025, and -$40.0 million in Q2 2025.